NASDAQ
32.89USD
+0.87 (+2.72%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.4B
P/E
—
EPS
—
Beta
0.95
52W range
19.277-56.05
Day range
32.09–33.09
Open
32.81
Prev close
32.02
Volume
1.5M
Avg volume
1.6M
Dividend
0.00
IPO
2021-05-14
https://www.marketbeat.com/instant-alerts/vera-therapeutics-wins-fda-approval-for-trutakna-in-iga-nephropathy-sets-launch-2026-07-11/ · 7/11/2026+1.00
https://www.marketbeat.com/originals/3-biotech-firms-with-major-potential-catalysts-in-the-coming-months/ · 6/21/2026+0.60
https://www.fool.com/coverage/filings/2026/03/16/this-biotech-stock-surged-75-last-quarter-and-pulled-a-new-usd9-million-investment/ · 3/16/2026+0.80
https://www.fool.com/coverage/filings/2026/03/13/this-fund-bet-usd200-million-on-a-biotech-stock-up-50-as-kidney-disease-drug-targets-july-7-fda-decision/ · 3/13/2026+0.80
https://seekingalpha.com/article/4873048-vera-hold-rating-based-on-potential-for-atacicept-in-igan-rating-downgrade · 2/20/2026
https://www.globenewswire.com/news-release/2025/11/26/3195386/0/en/Vera-Therapeutics-Appoints-Veteran-Biotech-Executive-James-R-Meyers-to-its-Board-of-Directors.html · 11/26/2025+0.60
https://seekingalpha.com/article/4839973-vera-therapeutics-inc-vera-discusses-interim-results-of-origin-phase-3-trial-of-atacicept-for · 11/7/2025+0.50
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
